EPISODE 04


EPISODE 04
9/15/24, 12:00 PM
In this episode of the Only Healthcare podcast, Dr. Randy Vogenberg and Michael Navin dive deep into the GLP-1 drug category, exploring the rapid growth and market evolution surrounding these diabetes and obesity management medications. This conversation sheds light on the opportunities and challenges faced by employers, manufacturers, and patients in managing these high-demand and high-cost treatments.
In this episode of the Only Healthcare podcast, Dr. Randy Vogenberg and Michael Navin dive deep into the GLP-1 drug category, exploring the rapid growth and market evolution surrounding these diabetes and obesity management medications. This conversation sheds light on the opportunities and challenges faced by employers, manufacturers, and patients in managing these high-demand and high-cost treatments.
Key Topics Covered:
The Explosive Growth of GLP-1 Drugs:
These drugs have become game-changers for patients with metabolic conditions, but they also bring unique challenges in managing costs and access for employers and health plans.
Employer Perspectives on Managing Costs:
As employers seek cost-effective solutions, they are faced with decisions on drug coverage, particularly for patients with obesity but without a diabetes diagnosis.
The Role of PBMs and Manufacturers:
The episode highlights the often-contentious relationship between PBMs and drug manufacturers.
Downstream Benefits of GLP-1 Drugs:
Beyond managing diabetes, GLP-1 drugs are also showing promise in improving cardiovascular health and overall metabolic profiles. Explore the broader benefits of these drugs and what future indications might look like, with a particular focus on the evolving clinical evidence.
The Patient's Journey:
The discussion touches on the importance of behavioral change, diet, and exercise in achieving optimal outcomes with GLP-1 medications.
What’s Next for GLP-1 and Metabolic Treatments:
The episode wraps up with a forward-looking perspective, as Randy and Michael consider the future of GLP-1 drugs, including the potential for direct-to-patient programs from manufacturers, compounded pharmacy solutions, and the evolving market as more players enter the space.
Listen Now:
Tune in to learn how employers, manufacturers, and healthcare stakeholders can navigate the complexities of the GLP-1 market while balancing cost, access, and patient outcomes.
For feedback or to suggest topics for future episodes, reach out to us at Only Healthcare Podcast.
Hosted by:
Michael Navin & Dr. Randy Vogenberg
Michael's LinkedIn
Randy's LinkedIn
Sponsored by:
Peek: A game-changing prescription shopping solution that allows its members to view all their prescription cost options across cash discount programs and their insurance in one easy-to-use platform. Peek is currently being offered to organizations to help both employees and plan sponsors save money on their prescription spend. https://peekmeds.com/.
Institute for Integrated Health (IIH): Health care benefits, insurance coverage regulations, and doing business in the healthcare industry can be complicated. At IIH, Dr. Randy Vogenberg and his team understand these unique challenges and provides strategic guidance customized to every client. To help overcome your unique challenges, IIH delivers education, planning and advisory on market trends, and U.S. health care market intelligence. The firm’s decades of proven success are due to strategic collaboration with associates from the business, clinical, and scientific communities. https://iih-online.com/.
Music by:
Hanu Dixit, https://www.youtube.com/hanudixit